Clinical TrialJun 16, 2026, 04:17 PM
Opus Genetics highlights 5 gene therapy programs; 4 data readouts by 2027
AI Summary
Opus Genetics highlighted five gene therapy programs for inherited retinal diseases (IRDs) at its R&D Science Forum, with four clinical data readouts anticipated in 2027. The company expects three new programs (OPGx-RDH12, OPGx-MERTK, OPGx-RHO) to enter clinical testing within the next 12-18 months. Opus Genetics also reported a cash runway extending into 2029, which is expected to fund multiple clinical milestones and potential product approvals.
Key Highlights
- Opus Genetics highlighted five gene therapy programs targeting inherited retinal diseases (IRDs).
- Four clinical data readouts are expected across the pipeline in 2027.
- OPGx-RDH12 program is expected to initiate clinical testing in the U.S. in Q4 2026.
- OPGx-MERTK program is expected to initiate clinical testing in Abu Dhabi in Q1 2027.
- OPGx-RHO program is expected to initiate clinical testing globally in H2 2027.
- OPGx-LCA5 pivotal Phase 3 trial dosing is expected to start in Q4 2026.
- OPGx-BEST1 Phase 1/2 Cohort 1 three-month topline data is expected in September 2026.
- Cash runway is expected to extend into 2029, funding multiple clinical inflection points.
Price Impact
More from IRD